Literature DB >> 17437273

Risk of human T-lymphotropic virus type I-associated diseases in Jamaica with common HLA types.

James J Goedert1, Hong-Chuan Li, Xiao-Jiang Gao, Nilanjan Chatterjee, Shunro Sonoda, Robert J Biggar, Beverley Cranston, Norma Kim, Mary Carrington, Owen Morgan, Barrie Hanchard, Michie Hisada.   

Abstract

Human T-lymphotropic virus-I (HTLV-I) causes adult T-cell leukemia/lymphoma (ATL) and HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP). We postulated a higher disease risk for people with common human leukocyte antigen (HLA) types, due to a narrower immune response against viral or neoplastic antigens, compared to people with uncommon types. HLA class-I (A,B) and class-II (DRB1, DQB1) allele and haplotype frequencies in 56 ATL patients, 59 HAM/TSP patients and 190 population-based, asymptomatic HTLV-I-infected carriers were compared by logistic regression overall (score test) and with odds ratios (ORs) for common types (prevalence >50% of asymptomatic carriers) and by prevalence quartile. HTLV-I proviral load between asymptomatic carriers with common versus uncommon types was compared by t-test. ATL differed from asymptomatic carriers in overall DQB1 allele and class-I haplotype frequencies (p </=</= 0.04). ATL risk was increased significantly with common HLA-B (OR 2.25, 95% CI 1.19-4.25) and DRB1 (OR 2.11, 95% CI 1.13-3.40) alleles. Higher prevalence HLA-B alleles were associated with higher ATL risk (OR 1.14 per quartile, p(trend) = 0.02). Asymptomatic carriers with common HLA-B alleles had marginally higher HTLV-I proviral load (p = 0.057). HAM/TSP risk did not differ consistently with common HLA types. Thus, ATL risk, but not HAM/TSP risk, was increased with higher prevalence HLA-B alleles. Perhaps breadth of cellular immunity affects risk of this viral leukemia/lymphoma. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437273     DOI: 10.1002/ijc.22767

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

2.  Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1.

Authors:  Ana Treviño; Jose L Vicario; Mariola Lopez; Patricia Parra; Rafael Benito; Raul Ortiz de Lejarazu; Jose M Ramos; Jorge Del Romero; Carmen de Mendoza; Vincent Soriano
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

3.  Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection.

Authors:  Melissa T Bartman; Zhanna Kaidarova; Dale Hirschkorn; Ronald A Sacher; Joy Fridey; George Garratty; Joan Gibble; James W Smith; Bruce Newman; Anthony E Yeo; Edward L Murphy
Journal:  Blood       Date:  2008-08-28       Impact factor: 22.113

4.  HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina.

Authors:  Paula Benencio; Sindy A Fraile Gonzalez; Nicolás Ducasa; Kimberly Page; Carolina A Berini; Mirna M Biglione
Journal:  Retrovirology       Date:  2020-09-03       Impact factor: 4.602

5.  In contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retroviral infection.

Authors:  Geraldine M O'Connor; Nafisa-Katrin Seich Al Basatena; Viviana Olavarria; Aidan MacNamara; Alison Vine; Qi Ying; Michie Hisada; Bernardo Galvão-Castro; Becca Asquith; Daniel W McVicar
Journal:  Hum Immunol       Date:  2012-05-17       Impact factor: 2.850

Review 6.  Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections.

Authors:  Tatiane Assone; Arthur Paiva; Luiz Augusto M Fonseca; Jorge Casseb
Journal:  Viruses       Date:  2016-02-03       Impact factor: 5.048

Review 7.  Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons.

Authors:  Antonio Carlos Rosário Vallinoto; Izaura Cayres-Vallinoto; Maria Alice Freitas Queiroz; Marluísa de Oliveira Guimarães Ishak; Ricardo Ishak
Journal:  Viruses       Date:  2019-10-23       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.